Reported Thursday September 12, 2024, Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 a.m. ET
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics will present Phase 2 data of NTLA-2002 for hereditary angioedema at the 2024 ACAAI Annual Meeting. The study met all primary and secondary endpoints. An investor webcast is scheduled for October 28.
September 17, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics will present detailed Phase 2 results of NTLA-2002, which met all study endpoints, at the ACAAI Annual Meeting. An investor webcast is scheduled for October 28.
The announcement of successful Phase 2 results for NTLA-2002, which met all endpoints, is likely to positively impact Intellia's stock price. The upcoming presentation and investor webcast could further boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100